Prolactinoma-associated headache: Clinical and radiological correlates and long-term outcomes
Authors' conclusion
PAH is most strongly linked to tumor invasiveness rather than to prolactin levels alone. Durable headache relief is achieved with both upfront surgical and medical therapy, suggesting that effective tumor control, rather than the specific initial treatment approach, is the key determinant of headache improvement. These findings support careful patient counseling and underscore the importance of an individualized multidisciplinary approach in prolactinoma patients presenting with headache.
Study context
- Population
- Patients with prolactinoma treated at a tertiary centre
- Participants
- 145 patients
- Exposure
- Upfront dopamine agonist (DA) therapy vs upfront transsphenoidal surgery
- Outcome
- Determinants of prolactinoma-associated headache (PAH) at diagnosis and long-term headache outcome by primary treatment strategy
Methodological detailssingle tertiary centre
- Single tertiary centre
Main finding
As reported in the abstract
Prolactinoma-associated headache (PAH) at diagnosis
42 of 145
28.9%
Cavernous sinus involvement, only independent factor associated with PAH: aOR
7.8 (1.2-48.7); p = 0.03 (95% CI)
Observational data: associations, not effects.
Further findings
Headache prevalence, long-term · median follow-up 80 months
- Headache prevalence declined
- 28.9% to 2.8% (p < 0.001)
- Durable headache improvement after both DA and TSS, no significant difference between treatments
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →